Mereo BioPharma (MREO) Total Current Liabilities (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Total Current Liabilities of $6.2 million for Q1 2026, down 17.61% year-over-year from $7.5 million in Q1 2025, and up 43.58% quarter-over-quarter from $4.3 million in Q4 2025.
Mereo BioPharma (MREO) Total Current Liabilities (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Total Current Liabilities for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 17.61% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (down 17.61% YoY), while the FY2025 annual figure was $4.3 million, down 68.93% from the prior year.
- Total Current Liabilities improved to $6.2 million in Q1 2026 per MREO's latest filing, from $4.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $44.3 million in Q2 2022 and bottomed at $4.3 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $14.7 million across 5 years, with a median of $11.0 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 221.32% — and 2025, when it tumbled 68.93%.
- Mereo BioPharma's Total Current Liabilities stood at $28.9 million in 2022, then tumbled by 67.23% to $9.5 million in 2023, then jumped by 45.98% to $13.8 million in 2024, then plunged by 68.93% to $4.3 million in 2025, then soared by 43.58% to $6.2 million in 2026.
- Business Quant data shows MREO's Total Current Liabilities at $6.2 million in Q1 2026, $4.3 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.68 Mn |
| Mar 31, 2026 | 6.18 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 6.02 Mn |
| Jun 30, 2025 | 7.56 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Dec 31, 2024 | 13.85 Mn |
| Sep 30, 2024 | 14.21 Mn |
| Jun 30, 2024 | 15.47 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 9.49 Mn |
| Jun 30, 2023 | 21.85 Mn |
| Dec 31, 2022 | 28.94 Mn |
| Jun 30, 2022 | 44.34 Mn |
| Dec 31, 2021 | 16.91 Mn |
| Jun 30, 2021 | 13.80 Mn |
| Dec 31, 2020 | 11.31 Mn |
| Jun 30, 2020 | 27.69 Mn |
| Dec 31, 2019 | 38.41 Mn |
| Jun 30, 2019 | 27.09 Mn |